Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 3:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Renal Impaired Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Dabrafenib in Subjects With Renal Impairment

NCT02852239
View directory record Official record
Conditions
Renal Impairment
Interventions
dabrafenib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
3
States / cities
DeBary, Florida • Berlin, New Jersey • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Sep 29, 2026, 3:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetics and Safety Study of Naproxcinod in Subjects With Impaired Renal Function

NCT00674856
View directory record Official record
Conditions
Renal Failure
Interventions
naproxcinod
Drug
Lead sponsor
NicOx
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
3
States / cities
Orlando, Florida • Minneapolis, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 27, 2009 · Synced Sep 29, 2026, 3:42 AM EDT
Completed Phase 2 Interventional Results available

42-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia

NCT01381094
View directory record Official record
Conditions
Anemia, Kidney Disease
Interventions
AKB-6548, Placebo
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 79 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
28
States / cities
Pine Bluff, Arkansas • Covina, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Sep 29, 2026, 3:42 AM EDT
Terminated Phase 1 Interventional

To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.

NCT02679131
View directory record Official record
Conditions
Relapsed/Refractory Solid Tumors/Hematological Malignancies
Interventions
Belinostat
Drug
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Whittier, California • Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Sep 29, 2026, 3:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment

NCT00750620
View directory record Official record
Conditions
Renal Impairment
Interventions
YM178
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 79 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Anaheim, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Sep 29, 2026, 3:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate EDG-7500 in People With Renal Impairment

NCT07034768
View directory record Official record
Conditions
Renal Impairments
Interventions
EDG-7500
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 29, 2026, 3:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal Function

NCT05404542
View directory record Official record
Conditions
Renal Impairment
Interventions
Tavapadon
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Jacksonville, Florida • Miami, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Sep 29, 2026, 3:42 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)®

NCT05900050
View directory record Official record
Conditions
Acute-On-Chronic Liver Failure, Ascites
Interventions
VS-01 on top of SOC, SOC (Control Group)
Drug · Other
Lead sponsor
Genfit
Industry
Eligibility
18 Years to 79 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
13
States / cities
Sacramento, California • Washington D.C., District of Columbia • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 29, 2026, 3:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics (PK) of RO7079901

NCT02975388
View directory record Official record
Conditions
Renal Impairment
Interventions
RO7079901
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
5
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2017 · Synced Sep 29, 2026, 3:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Renal Function Impairment on the Pharmacokinetics of LEE011

NCT02431481
View directory record Official record
Conditions
Normal Renal Function, Impaired Renal Function
Interventions
LEE011
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 29, 2026, 3:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of PK and Safety of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Subjects With Various Degrees Of Renal Function

NCT04178577
View directory record Official record
Conditions
Renal Impairment
Interventions
Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)
Drug
Lead sponsor
Spero Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 26, 2020 · Synced Sep 29, 2026, 3:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Evaluation of Tirofiban Using a Single High-Dose Bolus In Subjects With Varying Degrees of Renal Function

NCT01766154
View directory record Official record
Conditions
Renal Insufficiency
Interventions
Tirofiban
Drug
Lead sponsor
Medicure
Industry
Eligibility
18 Years to 85 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
DeLand, Florida
Source: ClinicalTrials.gov public record
Updated Mar 26, 2014 · Synced Sep 29, 2026, 3:42 AM EDT
Withdrawn No phase listed Observational

Calcium, Phosphate, Renal Impairment and Coronary Artery Disease in the Cardio-renal Syndrome, The CAPRICORN-CRS Study

NCT00853541
View directory record Official record
Conditions
Heart Failure
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Sep 29, 2026, 3:42 AM EDT
Active, not recruiting Phase 3 Interventional

Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

NCT06297603
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Retatrutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
28
States / cities
Huntsville, Alabama • Sun City West, Arizona • Apple Valley, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 29, 2026, 3:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Trial Evaluating OPC-34712 in Subjects With Normal Renal Function and Renally Impaired Subjects

NCT01289080
View directory record Official record
Conditions
Schizophrenia, Psychiatric Disorders
Interventions
OPC-34712
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Miami, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Sep 29, 2026, 3:42 AM EDT
Recruiting Phase 1 Interventional

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

NCT04953897
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
ASTX727
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 29, 2026, 3:42 AM EDT
Recruiting Not applicable Interventional

Feasibility and Plausible Effectiveness of a Lifestyle Intervention in Kidney Transplant Recipients (HEAL)

NCT06640179
View directory record Official record
Conditions
Kidney Transplant, Overweight or Obese Adults, Glucose Control
Interventions
Standard medical care, Monitoring Contacts, Behavioral Sessions, Diet, Physical Activity
Other · Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 29, 2026, 3:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study of Aztreonam-Avibactam in Severe Renal Impairment

NCT04486625
View directory record Official record
Conditions
Renal Insufficiency
Interventions
Aztreonam-Avibactam
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Sep 29, 2026, 3:42 AM EDT
Completed Phase 3 Interventional Results available

Safety and Diagnostic Efficacy of Mangoral in Participants With Focal Liver Lesions and Reduced Kidney Function

NCT04119843
View directory record Official record
Conditions
Known or Suspected Focal Liver Lesions, Severe Renal Impairment
Interventions
Mangoral
Drug
Lead sponsor
Ascelia Pharma AB
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
14
States / cities
Scottsdale, Arizona • Los Angeles, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Sep 29, 2026, 3:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone (MNTX) in Subjects With Impaired Renal Function

NCT01367509
View directory record Official record
Conditions
Renal Impairment
Interventions
Methylnaltrexone (MNTX)
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Sep 29, 2026, 3:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Renal Impairment Affects the Pharmacokinetics of PF-07817883.

NCT06586216
View directory record Official record
Conditions
COVID-19
Interventions
PF-07817883
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 90 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
3
States / cities
Miami, Florida • Tampa, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Sep 29, 2026, 3:42 AM EDT
Active, not recruiting Not applicable Interventional

Curcumin in Kidney Transplant Recipients

NCT03935958
View directory record Official record
Conditions
Disorder Related to Renal Transplantation
Interventions
Curcumin, Placebo
Dietary Supplement · Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 29, 2026, 3:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Observational Pharmacokinetic Study Of GW679769 In Subjects With Renal Impairment

NCT00358813
View directory record Official record
Conditions
Vomiting
Interventions
Casopitant
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
3
States / cities
Miramar, Florida • Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 3, 2017 · Synced Sep 29, 2026, 3:42 AM EDT
Completed Phase 4 Interventional

Dapagliflozin Treatment in Type 2 Diabetes

NCT04620590
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Impaired Renal Function
Interventions
Dapagliflozin 10 MG [Farxiga]
Drug
Lead sponsor
Emerald Clinical Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Sep 29, 2026, 3:42 AM EDT